论文部分内容阅读
目的构建survivin基因修饰DCs疫苗,并观察其生物学特性及其对喉癌治疗作用。方法通过同源重组构建人全长survivin-腺病毒载体(pAd-survivin),并转染未成熟DCs,诱导培养获取成熟DCs,激活T淋巴细胞的增殖;观察DCs疫苗在体内外的生物学活性。结果重组pAd-sur修饰DCs疫苗能显著刺激T淋巴细胞增殖;pAd-sur-DCs能促进T淋巴细胞IFN-γ分泌增加,与对照组比较差异具有显著意义;疫苗对体外细胞杀伤率51.46%,与对照组比较,差异具有显著意义;对移植瘤细胞凋亡率为54.9%,坏死率为21.87%,与对照组比较,差异具有显著意义。结论经survivin基因修饰后,DCs表面分子的表达率较未经基因修饰DCs显著增高,具备更强的刺激T淋巴细胞增殖,促进IFN-γ分泌;在体内外具有促进杀伤喉癌细胞的能力。
Objective To construct survivin gene modified DCs vaccine and observe its biological characteristics and its therapeutic effect on laryngeal cancer. Methods Human full-length survivin-adenovirus vector (pAd-survivin) was constructed by homologous recombination and transfected into immature DCs to induce mature DCs and activate T lymphocyte proliferation. The biological activity of DCs vaccine in vitro and in vivo . Results Recombinant pAd-sur modified DCs vaccine can significantly stimulate the proliferation of T lymphocytes; pAd-sur-DCs can promote T lymphocyte IFN-γ secretion increased compared with the control group was significant difference; vaccine in vitro cell killing rate of 51.46% Compared with the control group, the difference was significant; the apoptosis rate of the transplanted tumor cells was 54.9%, the necrosis rate was 21.87%, compared with the control group, the difference was significant. Conclusion The expression of survivin gene on DCs is significantly higher than that of non-genetically modified DCs, which stimulates the proliferation of T lymphocytes and promotes the secretion of IFN-γ. The ability of promoting the killing of laryngeal carcinoma cells in vitro and in vivo is also demonstrated.